Marico — a coconut-oil cash machine, fully priced
Marico Limited
Snapshot
Marico makes the everyday stuff in an Indian bathroom and kitchen: Parachute coconut oil (62% of the branded market — one in every two bottles), Saffola cooking oil and oats, value-added hair oils, plus a newer basket of online-first brands (Beardo, Plix, True Elements). Market cap ₹1,06,084 Cr, share price ₹817 (52-week range ₹688–₹849, so it sits right near the top). It earns a stunning 43% return on equity (profit per ₹100 of owners’ money) and 47% return on capital, on a balance sheet with almost no debt. But you pay for it: P/E 60×, price-to-book 25×.
What kind of animal is it? A Great franchise — a fountain of cash that needs very little capital to run. The whole question is the price tag.
As of 2026-06-20, from screener snapshot.
The verdict in one box
| Lens | Result |
|---|---|
| QGLP score | 19.5 / 25 (Quality 11/12 · Growth 4/6 · Longevity 4.5/5 · Price 0/2) |
| Buffett rubric | 8 / 10 PASS (the one clean fail is price) |
| Business bucket | Great |
| Wealth-creator type | Enduring · Consistent |
| Economic Profit | +₹1,305 cr (RoE 43% − CoE 12% on ₹4,210 cr net worth) — creating real value |
| Margin-of-safety price band | Quality-fair ₹600–₹700 (its own ~45× median). CMP ₹817 is demanding |
A Great business that genuinely creates wealth — currently priced richer than the quality, with the share near its all-time high while margins are at a cyclical low.
In plain English
Imagine you owned a little shop that sold one product almost everyone needs, where half the buyers in the country reach for your brand without thinking. You’d barely need to spend money to keep it running, and most of the cash it made would land in your pocket every year. That’s Parachute coconut oil, and that’s Marico. The business throws off more cash than it earns in accounting profit, carries almost no debt, and turns every ₹100 of owners’ money into ₹43 of profit a year. There are perhaps a dozen businesses in India this good. This is one of them.
The moat is a brand and a delivery van. Parachute has been the trusted, “pure” coconut oil for forty years; it reaches nearly five million shops. A new rival can copy the bottle but not the habit or the distribution. You can see the moat in the numbers — Marico has earned far more on its capital than it costs, every single year for at least a decade. That is the rarest thing in business: a castle the competition keeps failing to storm.
But this past year tested the castle. Coconut is the one raw material Parachute can’t do without, and its price (copra, the dried coconut) more than doubled — management called it “unprecedented hyperinflation.” Marico made a deliberate choice: protect how many bottles it sells rather than how much it makes per bottle. It pushed through roughly 30% of price hikes and shrank pack sizes, and still grew volume at the fastest pace in seven years (+8%). The cost of that choice was margin — profit per rupee of sales fell from about 21% to 17%. The good news as of early 2026: copra has cooled ~35–40% off its peak, so the squeeze should reverse through FY27. That margin payback is the single biggest thing to watch.
Around the old core, management is building a second engine — premium foods (Saffola oats, Plix, True Elements) and online-first personal care (Beardo). It’s still small and barely profitable, but it’s scaling fast (to a ~₹1,100 cr annual run-rate) and it’s where the growth will come from, because coconut and hair oil are mature, slow-moving categories. That’s the honest tension in the growth story: a magnificent, slow core plus a fast, unproven add-on.
So here’s the one-line tension. The business is wonderful and the people running it are, by the public record, honest and disciplined. The problem is the price. At 60× earnings for a company that has grown profits about 10% a year, you are paying a champion’s price for a steady jogger. As Buffett would put it: a wonderful business, but — today — at an unwonderful price.
Sitting down with the management
If you sat across the table from these people, you’d come away impressed — and you’d keep one eyebrow slightly raised.
Start with the founder. Harsh Mariwala took a sleepy family commodity business (Bombay Oil) and, in 1990, deliberately carved out the consumer arm because the old firm was, in his own words, “highly constrained by family management.” Read that again — a promoter who removed his own family from the controls because it was the right thing for the business. He then did the thing most Indian founders never do: he hired a professional, Saugata Gupta, and actually handed him the keys. Gupta has now run Marico for 12 years and just had his term renewed again. Harsh stayed on as Chairman to set direction and went off to build the Marico Innovation Foundation and ASCENT (a peer-mentoring network for entrepreneurs) and write a candid book about the whole journey. This is a man who treats the business as a craft, not a piggy bank.
How have they spent the owners’ money over a decade? Mostly well. They cut loose the loss-making Kaya skin-clinics business in 2013 rather than nurse it — the rare discipline to shrink. They’ve bought into online-first brands (Beardo, Plix, True Elements, Cosmix) using a smart “buy a minority stake, scale it with the founders, then buy the rest” model, and the early ones (Beardo, Plix) have multiplied several times over. Bangladesh, their overseas jewel, is a genuinely high-quality, cash-generative business. And they return cash generously — an ~83% dividend payout most years, meaning they don’t hoard money they can’t use well. Each retained rupee has, by the evidence of a sustained 40%-plus return on equity, made more than a rupee. The one-dollar test passes.
The accounts are clean. Profit turns into actual cash year after year (operating cash flow has run 86–114% of operating profit). There’s effectively no promoter share pledging. No auditor drama, no SEBI run-ins, no related-party games that I could find. On the WCS-24 forensic checklist — profit that never becomes cash, a ballooning balance sheet, pledging, auditor flags — nothing fires. The one yellow flag worth naming honestly: in 2022 a proxy-advisory firm objected that Harsh Mariwala’s ~₹3.9 cr chairman commission was “excessive” for a non-executive role, and the CEO’s pay sits above the sector median. It’s a niggle, not a scandal — but a part-owner should know it’s there.
The real risk is subtler: key-man and succession. The company is bigger than any one person operationally, thanks to the professional bench. But the Mariwala name still anchors the whole governance ethos, and his son Rishabh is kept (deliberately and wisely) in investing, not operations. There’s no visible operating heir at the chairman level. That’s not a problem today; it’s a question for the next decade.
Would Buffett and Agrawal shake hands on this management? Yes — readily. These are honest, capable, owner-minded people running a business they clearly love. The one thing that would change their mind: if the pace of online-brand acquisitions started outrunning the discipline — paying up for “diworsification” to chase a growth headline — or if the chairman-pay niggle grew into a pattern. Neither has happened. So far, they’ve earned the trust.
What’s on the horizon (live-issues tracker)
1. The copra (coconut) cost shock and the margin payback — 🟡 turning the corner
This is the whole FY26 story. Copra prices roughly doubled (~113% YoY at the worst, ~130% over two years), and it crushed gross margin — down ~810 basis points year-on-year in the September 2025 quarter. Marico chose volume over margin, took ~30% of cumulative price hikes on Parachute, and cut pack sizes (“shrinkflation”). It worked on volume (+8%, a 7-year high) but earnings barely grew. How it’s tracking: the worst is past. Gross margin rose sequentially +90 bps (Dec-25) then +140 bps (Mar-26) as copra eased ~35–40% off its peak. Management guides ~150–200 bps of EBITDA margin recovery in FY27. Watch: the March-2026 new-crop harvest and whether the sequential margin recovery accelerates. Bull: copra normalises and a year of margin tailwind drops straight to profit. Bear: coconut is structurally short in India; if prices stay sticky-high, the payback keeps slipping right.
2. The second engine — Foods + digital-first brands — 🟡 scaling, not yet proven on profit
Management wants the online-first portfolio at 2.5× its FY24 size by FY27 (5× by FY30) and digital brands at ≥25% of the India business within ~3 years. How it’s tracking: the digital run-rate has gone from ~₹400 cr (late FY24) to ~₹1,100 cr (end-FY26), and the Foods portfolio crossed ₹1,000 cr in revenue. That’s real momentum. The catch: profitability. These brands are guided to only reach double-digit margins by FY27 and “teens” by FY30 — today they dilute the group’s blended margin. They spent ~₹1,300 cr on advertising in FY26 to feed this. Watch: True Elements and Plix hitting breakeven (guided ~18 months) and the 2.5× FY27 revenue milestone landing on time. Bull: this is the growth runway a mature core lacks. Bear: D2C is a cash-hungry, crowded game; the targets are guidance, not yet banked.
3. Volume-led growth + rural recovery — 🟢 on track
Underneath the price-driven optics, the real signal is healthy: India volume +8% for FY26, with rural India growing roughly twice as fast as urban for several straight quarters (good monsoon, higher crop prices, income-tax relief feeding back into spending). FY26 revenue grew ~25.7% to ₹13,611 cr (mostly price), and management expects volume momentum to hold as pricing moderates. Watch: whether urban demand joins the rural strength to sustain high-single-digit volume into FY27. This is the most clearly-working thread of the three.
The watch-list (check next quarter):
- Gross margin sequential recovery — is it still climbing past the +140 bps QoQ pace? (FY27 EBITDA target ~150–200 bps up)
- Copra price vs the March-2026 new-crop flush — has it stayed 35%+ below peak?
- Digital-first run-rate crossing the FY27 “2.5× FY24” milestone, and True Elements/Plix breakeven.
- India volume growth holding high-single-digit with pricing fading.
- Any creep in the D2C acquisition pace or price paid — the discipline tell.
QGLP scorecard (the Motilal Oswal lens) — the receipts
| # | Question | Score | Evidence |
|---|---|---|---|
| Quality of Business | 6/6 | ||
| 1 | Large opportunity? | 1 | India FMCG huge, low per-capita; foods/premiumisation runway (about) |
| 2 | Industry structured favourably? | 1 | Branded, consolidated; OPM stable 18–21% for a decade (profit_loss) |
| 3 | Defensible moat? | 1 | Parachute 62% coconut-oil share; RoCE 38–47% every year 10/10 (ratios_table) |
| 4 | High return ratios (>15%)? | 1 | RoE 43%, RoCE 47.2%; both >15% all 10+ years (ratios) |
| 5 | Asset-light? | 1 | FCF ₹1,772 cr ≈ 98% of PAT ₹1,813 cr; low capex/OCF (cash_flow) |
| 6 | Favourable terms of trade? | 1 | Debtor 35d ≪ payable 79d → ToT ~44% (<100%); note WC has loosened (ratios_table) |
| Quality of Management | 5/6 | ||
| 7 | Unquestionable integrity? | 1 | OCF/OP 86–114%; nil pledging; clean auditor; no RPT leakage |
| 8 | Proven execution? | 1 | 12-yr professional CEO; crossed ₹10k cr (FY25), volume +8% FY26 |
| 9 | Growth mindset? | 1 | D2C buyouts, foods, ₹20k cr-by-2030 ambition |
| 10 | Superior capital allocation? | 1 | RoE sustained 40%+ through reinvestment; Kaya demerger; accretive D2C; ~83% payout |
| 11 | Clear succession? | 0.5 | Strong professional bench, but Mariwala-name key-man; no operating heir |
| 12 | Minority interests protected? | 0.5 | Generous dividends, nil pledging — but 2022 proxy flag on chairman commission |
| Growth | 4/6 | ||
| 13 | Structural tailwind? | 0.5 | FMCG ~GDP-plus, but coconut/hair-oil core is mature |
| 14 | Volume-led growth? | 0.5 | FY26 volume +8% (7-yr high) strong, but multi-year volume only mid-single-digit |
| 15 | Operating leverage? | 0.5 | OPM stable long-run but currently compressed (21%→17%), not expanding (profit_loss) |
| 16 | Manageable leverage? | 1 | Debt/equity 0.03; net cash (balance_sheet, AR FY25) |
| 17 | Market-share gain potential? | 1 | Gaining in VAHO, foods, digital; dominant in core |
| 18 | Earnings growth >15%? | 0.5 | PAT CAGR ~9–11% (3/5/10-yr) — solid but below 15% (profit_loss) |
| Longevity | 4.5/5 | ||
| 19 | Relevant for 10–15 yrs? | 1 | Staple consumption, low disruption risk |
| 20 | Extend CAP (moat)? | 1 | RoE durably ≫ cost of capital; brand + distribution widening |
| 21 | Sustain GAP (growth runway)? | 0.5 | Real runway in foods/digital/international; core categories saturated |
| 22 | Diversification headroom? | 1 | International (Bangladesh/Vietnam/MENA) + foods + digital |
| 23 | Adaptive, resilient culture? | 1 | Professionalised, innovation DNA, through-cycle track record |
| Price | 0/2 | ||
| 24 | Valuation reasonable (PEG)? | 0 | PEG ~6× (P/E 60 ÷ ~10% growth) |
| 25 | Margin of safety? | 0 | 5-yr payback ~8×; PEG ~6× — expensive on both |
| Total | 19.5/25 |
The pillar pattern: Quality is near-perfect (11/12) and Longevity excellent (4.5/5) — this is a genuine compounder. Growth is merely good (4/6): the core is mature and earnings grow ~10%, not 15%+. And Price is a clean zero. Strip out the price pillar and this is a textbook 19.5/23 wealth creator. The entire gap between this and a buy-zone is valuation.
Buffett lens (the Berkshire-letters read)
| # | Test | Verdict | Evidence |
|---|---|---|---|
| 1 | Good boat (business > management)? | PASS | Great FMCG franchise; RoCE 47%, tiny reinvestment need |
| 2 | Moat + pricing power? | PASS | Pushed ~30% price on copra spike, held volume; RoE > CoE 10/10 years |
| 3 | See’s test (high return, little capital)? | PASS | FCF ≈ 98% of PAT; capex ≪ operating cash flow |
| 4 | Capital allocation (one-dollar test)? | PASS | RoE 40%+ sustained through reinvestment; ~83% payout; no value-destroying M&A |
| 5 | Owner-oriented, candid management? | PASS | Founder professionalised the firm; clean disclosure (one chairman-pay niggle) |
| 6 | Integrity / forensic (no “credit P&L, debit B/S”)? | PASS | OCF backs profit; no balance-sheet bloat; nil pledging |
| 7 | Circle of competence / predictability? | PASS | A bottle of coconut oil — you know exactly what this is in 10 years |
| 8 | Mr. Market — gift or trap? | FAIL | P/E 60×, near 52-week high, PEG ~6× — the market is complacent, not fearful |
| 9 | Patience / compounding runway? | PASS | Foods + international + premiumisation give a real (if not explosive) runway |
| 10 | The honest red flag | (see Conviction texture) | — |
Score: 8 / 10 — Buffett-grade business; the only outright fail is price.
The See’s test, in numbers. See’s Candies was the business that taught Buffett to love brands that print cash without swallowing capital. Marico is cut from the same cloth. In FY26 it earned ₹1,813 cr of profit and generated ₹1,772 cr of free cash — roughly 98% of profit converted to spendable cash, after all capital spending. It runs on a net-worth of just ₹4,210 cr, so it earns 43% on the owners’ money. That’s the See’s signature: high returns on a small capital base, with the surplus free to be paid out or redeployed. It passes cleanly.
The one-dollar test, in numbers. Buffett’s rule: for every rupee a company keeps instead of paying out, it should create at least a rupee of market value. Marico keeps relatively little — it pays out ~83% — and what it keeps, it reinvests at 40%-plus returns, while the share has compounded for shareholders over the decade. The retained rupees have plainly created more than a rupee of value. Pass.
The framework metrics
- Economic Profit = Net Worth ₹4,210 cr × (RoE 43% − CoE 12%) = +₹1,305 cr of true value created above the cost of owners’ money. Strongly positive — a top-tier wealth creator on the economic-profit curve.
- Terms of Trade = Debtors ÷ Creditors ≈ 35 days / 79 days ≈ 44% → favourable; suppliers fund more than customers owe. Caveat: working-capital days have loosened (debtor days 11→43 over the decade, cash-conversion cycle now +34 days on copra stocking) — worth watching, not alarming.
- 5-yr Payback = Market cap ₹1,06,084 cr ÷ projected cumulative 5-yr PAT ≈ ₹13,300 cr = ~8.0× (assuming a generous 13% PAT CAGR). Far above the <1× multibagger signal — you wait ~8 years of earnings to pay back the price.
- PEG = P/E 60.2 ÷ ~10% growth = ~6.0×. Price discipline (PEG ≤ 1) badly failed.
- RoE − CoE spread = 43% − 12% = +31%, and RoE has exceeded 15% in 10 of the last 10 years. A wide, durable “uncommon profit.”
- Consistent / Volatile test = Consistent. Over 11 years, profit fell only once (FY20, −7.8%, < the 10% threshold), never by >50%, and FY26 PAT is 3× FY15. Value it on P/E, not P/B.
Peer comparison
| Company | Mcap (₹cr) | CMP (₹) | P/E | P/B | RoE | RoCE | OPM | Sales (₹cr) |
|---|---|---|---|---|---|---|---|---|
| Marico | 1,06,084 | 817 | 60.2 | 25.2 | 43.0% | 47.2% | 17% | 13,611 |
| HUL | 5,15,641 | 2,195 | 33.9 | 10.6 | 31.0% | 28.4% | 23% | 64,468 |
| Godrej Consumer | 1,02,386 | 1,001 | 50.5 | 8.1 | 16.5% | 19.1% | 21% | 15,178 |
| Dabur | 75,127 | 424 | 39.4 | 6.6 | 17.2% | 20.4% | 19% | 13,193 |
| Emami | 18,049 | 414 | 23.0 | 6.2 | 27.9% | 29.6% | 25% | 3,780 |
Peer snapshots as of 2026-06-20. Marico has the best return ratios and the cleanest balance sheet in the pack — partly real (asset-light, brand-led) and partly because its huge payout keeps book value small, which flatters RoE and inflates P/B. But it also carries the richest P/E (60×), above even Godrej (50×) and well above HUL (34×), Dabur (39×) and Emami (23×). Its current 17% margin is the lowest of the group — that’s the copra dent, and it should recover. The relative read confirms the absolute one: Marico is the quality and momentum leader, but it is not the value name in its asset class. If you want cheap-and-good, Emami screens far better (23× P/E, 28% RoE, 25% margins); HUL is the scale anchor. Marico’s distinctive edge is volume momentum + the digital-foods optionality — but you’re paying top-of-class for it.
Latest quarter & what’s happening now
Q4 FY26 (quarter ended March 2026, reported ~May 2026): revenue ₹3,333 cr (+22% YoY), India volume ~8–9% (a 7-year high), net profit ₹408 cr; EBITDA margin ~15.6% (−~114 bps YoY but recovering sequentially, gross margin +140 bps QoQ). Full-year FY26: revenue ₹13,611 cr (+25.7%), PAT ₹1,813 cr (+9.4%), volume +8%. [HARD, reported financials; some Q4 bps figures from secondary sources — confirm against Marico’s own release.]
Management’s posture: hold strong volume as pricing fades, with “progressive improvement in gross and operating margins” through FY27. FY27 framing: >₹15,000 cr revenue, high-single-digit volume, ~150 bps margin recovery. [SOFT — guidance.] Live catalysts: copra cooling ~35–40% off peak [HARD/SOFT]; income-tax relief and rural recovery feeding demand [SOFT]; digital-first run-rate at ~₹1,100 cr [HARD].
Where the two lenses agree — and disagree
They agree almost completely, which is the expected result for a high-quality compounder: QGLP scores 11/12 on quality, Buffett passes 8 of 10, both call it Great and Enduring, and both score the price a zero/fail. There’s no integrity divergence, no predictability divergence — the rare cases where a checklist and the letters part company. The only nuance is on growth: QGLP’s Growth pillar (4/6) and Buffett’s runway test (PASS) are slightly more generous than the raw ~10% earnings CAGR would suggest, because both lean on the optionality of foods and digital. If that second engine disappoints, the growth read is the part that softens. Everything else is aligned: a wonderful business, fairly judged on quality, sitting at a demanding price.
Margin-of-safety price band
Not a recommendation — the framework’s arithmetic.
- Strict QGLP floor (PEG ≤ 1×): with ~10–13% earnings growth, PEG = 1 implies a P/E of ~10–13× → roughly ₹160–₹220. The framework’s blunt way of saying: don’t pay a champion’s multiple for a 10% grower. You will essentially never see a 43%-RoE FMCG franchise at that price — but it marks how far CMP is from pure price discipline.
- Quality-fair zone (its own ~45–48× median P/E — where a patient owner pays up for the quality but Mr. Market isn’t greedy): ~₹600–₹700 on FY26–FY27 earnings.
- CMP ₹817 = P/E 60×, ~20–25% above its own historical median, near a 52-week high while margins sit at a cyclical low. Mr. Market is complacent here, not fearful. Demanding.
Plainly: a wonderful business at an unwonderful price. The quality is not in question; the entry price is. The interesting setup would be a “bruised blue chip” moment — a demand scare or a copra-driven earnings miss that drops it toward the ₹600s — not today’s near-record level.
Conviction texture
The bull case, at its strongest. You’re buying one of the dozen best consumer franchises in India — 62% share in its core, 43% return on equity, almost no debt, cash conversion near 100%, and honest, disciplined, owner-minded management. The copra squeeze that’s hiding the earnings is already reversing, so FY27 gets a margin tailwind on top of the best volume growth in seven years. And unlike a saturated giant, Marico has a fast-scaling second engine in foods and online-first brands that could re-rate the whole growth profile. Quality this durable, compounded for a decade, rarely stays cheap — so “fully priced” may simply be the toll for owning it.
The bear case, at its strongest (the honest red flag). The single strongest reason this isn’t a great investment today is that you’re paying 60× earnings for a business growing profits ~10% a year — and the numbers support that worry, not refute it. PEG ~6×, payback ~8×, P/E ~25% above its own median, share near an all-time high. The core categories (coconut and hair oil) are mature and grow at low-single-digit volumes; the exciting growth (foods, D2C) is still barely profitable and is guidance, not delivery. A coconut that stays expensive, or a digital engine that keeps diluting margins, and the market’s patience with a 60× multiple could evaporate fast — the price has a long way to fall before it’s “cheap.” Great business; the margin of safety is the missing ingredient.
What the numbers actually support: an Enduring, Consistent, Great wealth creator (EP +₹1,305 cr, RoE 43%, 10/10 years above hurdle) — trading at a price that already banks years of the good news.
Three things to watch that would tip it: (1) copra-driven gross-margin recovery accelerating into FY27; (2) the digital-foods portfolio actually crossing into double-digit margins on schedule; (3) the price — a drawdown toward the ₹600s on a demand or earnings scare is what would turn quality-you-admire into quality-you-can-own.
No buy/sell/hold — the reader decides.
Sources
- Screener.in: Marico consolidated — all financials, FY26 (year ended Mar 2026). Peers: HUL, Dabur, Godrej Consumer, Emami snapshots, 2026-06-20.
- Marico FY25 Annual Report (chairman/CEO letters, governance, segment, debt/equity 0.03) — BSE filing.
- Marico Q3/Q4 FY26 concall + investor updates; Q3 FY26 information update.
- Copra/margin: Business Standard, 17 Nov 2025; Angel One, Nov 2025.
- Digital/foods targets: Storyboard18; BestMediaInfo.
- Management: Harsh Mariwala (Wikipedia); CEO reappointment, Business Standard, 5 May 2025; chairman-pay flag: Business Today, 4 Aug 2022.
- Assumptions: Cost of Equity (CoE) = 12% (Indian benchmark; studies use 10–15%). 5-yr payback assumes 13% PAT CAGR. PEG uses ~10% trailing PAT growth. FY27 figures are management guidance (SOFT), not banked.